---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-11T23:22:02.396833'
end_time: '2026-01-11T23:29:10.628373'
duration_seconds: 428.23
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: DLX1
  gene_symbol: DLX1
  uniprot_accession: P56177
  protein_description: 'RecName: Full=Homeobox protein DLX-1;'
  gene_info: Name=DLX1;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the distal-less homeobox family. .
  protein_domains: Distal-less_Homeobox_TF. (IPR050460); HD. (IPR001356); HD_metazoa.
    (IPR020479); Homeobox_CS. (IPR017970); Homeodomain-like_sf. (IPR009057)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 29
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P56177
- **Protein Description:** RecName: Full=Homeobox protein DLX-1;
- **Gene Information:** Name=DLX1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the distal-less homeobox family. .
- **Key Domains:** Distal-less_Homeobox_TF. (IPR050460); HD. (IPR001356); HD_metazoa. (IPR020479); Homeobox_CS. (IPR017970); Homeodomain-like_sf. (IPR009057)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "DLX1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'DLX1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **DLX1** (gene ID: DLX1, UniProt: P56177) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P56177
- **Protein Description:** RecName: Full=Homeobox protein DLX-1;
- **Gene Information:** Name=DLX1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the distal-less homeobox family. .
- **Key Domains:** Distal-less_Homeobox_TF. (IPR050460); HD. (IPR001356); HD_metazoa. (IPR020479); Homeobox_CS. (IPR017970); Homeodomain-like_sf. (IPR009057)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "DLX1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'DLX1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **DLX1** (gene ID: DLX1, UniProt: P56177) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan and verification
We verified identity before research: DLX1 (UniProt P56177) encodes a human distal-less homeobox transcription factor with a conserved homeodomain (HD). DLX proteins are nuclear DNA-binding transcription factors recognizing TAAT/ATTA-like motifs, consistent with distal-less homeobox family/domain annotations (homeobox, homeodomain-like) and the Homo sapiens organism context (zhu2024 review excerpts) (zhu2024transgenicmodelsto pages 46-51, zhu2024transgenicmodelsto pages 51-56).

Key concepts and definitions with current understanding
- Molecular identity and DNA recognition: DLX1 is a homeobox transcription factor whose HD helices form an HTH-like fold that binds specific TAATTA-type motifs; DLX factors act as sequence-specific transcriptional regulators at enhancers and promoters in development (zhu2024transgenicmodelsto pages 46-51). In human neurons, overexpression of DLX1 reprograms promoter–enhancer multi-loops with motif dependence: DLX1 attenuates loops anchored by enhancers bearing 2+ TAATTA arrays and facilitates loops at sites with 0–1 TAATTA motif, providing functional evidence for motif grammar in DLX-dependent chromatin topology (bioRxiv, Feb 27, 2024; doi:10.1101/2024.02.27.582395) (chandrashekar2024amultiloopingchromatin pages 19-22).
- Cellular localization: As a transcription factor, DLX1 functions in the nucleus to regulate lineage programs; enhancer-centric activity and nuclear chromatin loop rewiring have been demonstrated in human neuronal models (chandrashekar2024amultiloopingchromatin pages 19-22).
- Core developmental role: DLX1, paired with DLX2, is a key regulator of GABAergic interneuron specification and migration in the ventral telencephalon. Loss- and gain-of-function studies in vertebrates show DLX1/2 promote GABA synthesis, synaptogenesis, dendritogenesis, and interneuron migration, with craniofacial expression in the pharyngeal arches linking to jaw/odontogenic patterning (zhu2024transgenicmodelsto pages 46-51, zhu2024transgenicmodelsto pages 51-56). A 2024 PNAS study reinforces the canonical sequence in which ASCL1 and DLX1/2 specify GABAergic identity before later fate determinants, and shows FoxG1 dosage acts as a developmental clock modulating interneuron trajectories, positioning DLX1/2 within conserved GRNs (PNAS, Apr 8, 2024; doi:10.1073/pnas.2317783121) (miyoshi2024developmentaltrajectoriesof pages 1-2).

Recent developments and latest research (2023–2024; prioritized)
- Human cortical development enhancers: Using lentiMPRA in primary mid-gestation human cortical cells and organoids, Science 2024 cataloged 46,802 active enhancers and identified TF families with enriched binding sites in neurodevelopmental elements, including DLX motifs, highlighting upstream regulatory grammar for cell-type–specific enhancer activity (Science, May 24, 2024; doi:10.1126/science.adh0559) (deng2024massivelyparallelcharacterization pages 7-8).
- Chromatin architecture and DLX1: In iPSC-derived human neurons, elevated DLX1/5/6 expression coincided with miswiring of promoter–enhancer multi-loops and an excitatory-to-inhibitory expression shift; causal DLX1 overexpression alone recapitulated motif-dependent loop loss/gain without changes in classical architectural proteins, arguing that DLX TFs can act as anti-loopers or loop facilitators depending on TAATTA motif multiplicity (bioRxiv, Feb 27, 2024; doi:10.1101/2024.02.27.582395) (chandrashekar2024amultiloopingchromatin pages 19-22).
- Interneuron developmental timing and GRNs: FoxG1 dynamics sequentially modulate GABAergic interneuron identity and migration; DLX1/2 are placed upstream in GABAergic specification in this dosage-sensitive framework (PNAS, 2024) (miyoshi2024developmentaltrajectoriesof pages 1-2). Complementary work mapping midbrain inhibitory neuron diversity identifies clusters marked by DLX1 expression and delineates migration dependencies (iScience, Nov 15, 2024; doi:10.1016/j.isci.2024.111239) (dudukcu2024moleculardiversityand pages 10-12).
- Prostate cancer epigenetic reprogramming: In CRPC models, non-canonical EZH2 forms coactivator complexes (including YY1) that reprogram the AR cistrome during enzalutamide resistance; lineage cell-fate TFs such as DLX1 appear in the reprogrammed AR network, contextualizing DLX1 within AR/EZH2-driven plasticity (Nature Communications, Nov 2024; doi:10.1038/s41467-024-53874-2) (chatterjee2024increasedtranslationdriven pages 10-11).
- Cancer outside prostate: DLX1 is upregulated in lung adenocarcinoma and associates with worse prognosis; knockdown reduces LUAD cell proliferation, migration, and invasion, supporting broader oncogenic roles (PeerJ, Feb 2024; doi:10.7717/peerj.16823) (du2024dlx1actsas pages 1-2).
- Early craniofacial patterning with human models: Human pluripotent stem cell–derived 3D branchial arch-like aggregates establish in vitro human craniofacial patterning platforms responsive to EDN1/BMP4, directly relevant to DLX-patterned maxillary/mandibular domains (Nature Communications, Feb 2024; doi:10.1038/s41467-024-45285-0) (seto2024invitroinduction pages 1-2).

Function, processes, localization, and pathways
- DNA binding and transcriptional control: DLX1 binds TAAT/ATTA-like motifs at enhancers and promoters to activate or repress lineage programs. In human neurons, DLX1 modulates promoter–enhancer contacts in a motif copy–dependent manner, linking sequence grammar to 3D genome function (chandrashekar2024amultiloopingchromatin pages 19-22). MPRA-based decoding of enhancer activity in the developing cortex independently identifies DLX motifs as key determinants of neurodevelopmental enhancer activity, consistent with DLX1 acting on those elements in vivo (deng2024massivelyparallelcharacterization pages 7-8).
- Cellular location of action: Nuclear; DLX1 engages chromatin and long-range enhancer–promoter interactions in neuronal lineage contexts (chandrashekar2024amultiloopingchromatin pages 19-22).
- Neurodevelopmental pathways: DLX1/2 are early nodes in the interneuron GRN, downstream of ASCL1 and interacting with other fate determinants (e.g., ARX, LHX6) to govern tangential/radial migration and laminar allocation; FoxG1 dosage provides a timing axis that interfaces with DLX1/2-driven identity programs (miyoshi2024developmentaltrajectoriesof pages 1-2, zhu2024transgenicmodelsto pages 46-51, zhu2024transgenicmodelsto pages 51-56). Human midbrain datasets resolve DLX1-marked inhibitory clusters and netrin-dependent migrations, situating DLX1 within broader inhibitory circuitry formation (dudukcu2024moleculardiversityand pages 10-12).
- Craniofacial/odontogenic development: DLX1/2 are expressed in first/second pharyngeal arches (maxillary and mandibular neural crest–derived mesenchyme) and are dosage sensitive for jaw morphogenesis; perturbation yields cleft palate and jaw defects in vertebrate models, consistent with DLX-patterned craniofacial domains (zhu2024transgenicmodelsto pages 51-56). Human in vitro branchial arch aggregates provide a manipulable system that recapitulates maxillary vs. mandibular patterning cues (seto2024invitroinduction pages 1-2).

Regulatory interactions in cancer and disease translational relevance
- AR/EZH2 axis and lineage plasticity: Under androgen receptor pathway inhibition, PKCλ/ι loss shifts EZH2 to a non-canonical coactivator state (with YY1), reprogramming AR cistrome and upregulating translation programs. Within this reprogrammed network, lineage TFs (including DLX1) appear among cell-fate regulators, consistent with reports that DLX1 participates in AR/β-catenin–linked oncogenic programs in prostate cancer (Nature Communications, 2024; doi:10.1038/s41467-024-53874-2; plus functional/associative evidence in LUAD) (chatterjee2024increasedtranslationdriven pages 10-11, du2024dlx1actsas pages 1-2).
- Chromatin looping and disease states: DLX1 overexpression alone is sufficient to miswire promoter–enhancer loops, implying a direct mechanism by which DLX1 dysregulation could reprogram cell identity or contribute to lineage plasticity across diseases (chandrashekar2024amultiloopingchromatin pages 19-22).

Current applications and real-world implementations
- Prostate cancer urine biomarkers: DLX1 mRNA in urine has been clinically adopted in multigene assays for risk stratification of prostate cancer. Contemporary biomarker reviews in 2024 specifically reference urinary DLX1 among transcriptomic biomarkers used to enhance diagnostic specificity beyond PSA (Biology, Sep 2024; doi:10.3390/biology13100762) (hachem2024contemporaryupdateon pages 7-8). Precision oncology overviews further note a two-gene urine test combining HOXC6 and DLX1 that provides risk assessment, reflecting real-world uptake of urinary transcript panels in clinical decision pathways (Cancer Imaging, 2025; doi:10.1186/s40644-025-00938-1) (min2025precisionmedicinein pages 7-9).
- DNA methylation triage in cervical cancer screening: Although not DLX1-specific alone, a clinically approved panel (GynTect) includes DLX1 among six genes for triage of hrHPV-positive women. A 2023 systematic review and meta-analysis reported pooled performance of DNA methylation triage markers for CIN2+/CIN3+ detection, with pooled AUCs of 0.79 for CIN2+ and 0.85 for CIN3+ using health professional–collected samples. These data demonstrate clinical-grade performance of methylation-based tests that include DLX1 (Clinical Epigenetics, Aug 2023; doi:10.1186/s13148-023-01537-2) (salta2023dnamethylationas pages 11-13).

Expert opinions and analysis from authoritative sources
- Science 2024 (MPRA) emphasizes TF motif grammar—including DLX family sites—as a determinant of human cortical enhancer function, underscoring the centrality of DLX factors in neurodevelopmental regulatory code and providing a vetted catalog of active elements and variant effects (deng2024massivelyparallelcharacterization pages 7-8).
- PNAS 2024 frames DLX1/2 within a dosage- and timing-sensitive interneuron GRN in which FoxG1 acts as a clock, aligning genetic studies of human neurodevelopmental disorders with mechanistic TF hierarchies (miyoshi2024developmentaltrajectoriesof pages 1-2).
- Nature Communications 2024 identifies a clinically actionable vulnerability in enzalutamide-resistant CRPC driven by non-canonical EZH2; the reprogrammed cistrome encompasses cell-fate TFs including DLX1, aligning with the notion that reactivation of developmental TFs (such as DLX1) contributes to lineage plasticity and therapeutic resistance (chatterjee2024increasedtranslationdriven pages 10-11).
- PeerJ 2024 provides independent tumor-system evidence that aberrant DLX1 expression promotes malignant phenotypes, expanding DLX1’s oncogenic relevance beyond prostate cancer (du2024dlx1actsas pages 1-2).

Relevant statistics and quantitative data (recent)
- Developing cortex enhancer activity catalog: 46,802 enhancer sequences active in human mid-gestation cortex defined; deep learning identified TFBS families including DLX as major contributors to activity; 164 disease-associated variants with differential enhancer activity were validated (Science, 2024) (deng2024massivelyparallelcharacterization pages 7-8).
- DLX1-driven loop rewiring: In human neurons, DLX1 overexpression yielded 1,590 control-specific loops lost vs. 277 DLX1-specific loops gained, with losses enriched at enhancers containing 2+ TAATTA motifs and gains at 0–1 motif sites (bioRxiv, 2024) (chandrashekar2024amultiloopingchromatin pages 19-22).
- Cervical cancer methylation triage performance: For CIN2+ detection, pooled sensitivity 0.70 (95% CI 0.65–0.74), specificity 0.76 (0.71–0.81), AUC 0.79 (0.75–0.82) with health professional–collected samples; for CIN3+, pooled sensitivity 0.81 (0.76–0.85), specificity 0.75 (0.70–0.79), AUC 0.85 (0.82–0.88) (Clinical Epigenetics, 2023) (salta2023dnamethylationas pages 11-13).

Concise functional annotation of DLX1 (human; UniProt P56177)
- Primary role: Nuclear homeobox transcription factor governing lineage programs in development; in the forebrain, an early regulator of GABAergic interneuron specification and migration, acting through enhancer binding to TAAT/ATTA-like motifs and collaborating within DLX-centered GRNs (zhu2024transgenicmodelsto pages 46-51, zhu2024transgenicmodelsto pages 51-56, miyoshi2024developmentaltrajectoriesof pages 1-2, deng2024massivelyparallelcharacterization pages 7-8).
- Cellular context of action: Nucleus of progenitors and differentiating neurons; exerts control via enhancer occupancy and chromatin loop modulation (chandrashekar2024amultiloopingchromatin pages 19-22, deng2024massivelyparallelcharacterization pages 7-8).
- Pathways: Interneuron specification networks (ASCL1→DLX1/2→ARX/LHX6 modules), craniofacial neural crest patterning in first/second pharyngeal arches, and, when dysregulated, participation in oncogenic networks including AR/EZH2-reprogrammed cistromes (miyoshi2024developmentaltrajectoriesof pages 1-2, zhu2024transgenicmodelsto pages 51-56, chatterjee2024increasedtranslationdriven pages 10-11).
- Disease links and applications: Overexpressed in certain cancers (e.g., LUAD) with functional oncogenic effects; deployed as a urinary transcript biomarker (with HOXC6) to stratify prostate cancer risk; included in methylation-based triage panels for cervical screening with documented pooled performance metrics (du2024dlx1actsas pages 1-2, hachem2024contemporaryupdateon pages 7-8, min2025precisionmedicinein pages 7-9, salta2023dnamethylationas pages 11-13).

URLs and publication dates (selection)
- Deng et al., Science, May 24, 2024. “Massively parallel characterization of regulatory elements in the developing human cortex” doi:10.1126/science.adh0559 (https://doi.org/10.1126/science.adh0559) (deng2024massivelyparallelcharacterization pages 7-8).
- Chandrashekar et al., bioRxiv, Feb 27, 2024. “A multi-looping chromatin signature…” doi:10.1101/2024.02.27.582395 (https://doi.org/10.1101/2024.02.27.582395) (chandrashekar2024amultiloopingchromatin pages 19-22).
- Miyoshi et al., PNAS, Apr 8, 2024. “Developmental trajectories of GABAergic cortical interneurons…” doi:10.1073/pnas.2317783121 (https://doi.org/10.1073/pnas.2317783121) (miyoshi2024developmentaltrajectoriesof pages 1-2).
- Chatterjee et al., Nature Communications, Nov 2024. “Increased translation driven by non-canonical EZH2…” doi:10.1038/s41467-024-53874-2 (https://doi.org/10.1038/s41467-024-53874-2) (chatterjee2024increasedtranslationdriven pages 10-11).
- Hachem et al., Biology, Sep 2024. “Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers…” doi:10.3390/biology13100762 (https://doi.org/10.3390/biology13100762) (hachem2024contemporaryupdateon pages 7-8).
- Du et al., PeerJ, Feb 2024. “DLX1 acts as a novel prognostic biomarker…” doi:10.7717/peerj.16823 (https://doi.org/10.7717/peerj.16823) (du2024dlx1actsas pages 1-2).
- Salta et al., Clinical Epigenetics, Aug 2023. “DNA methylation as a triage marker…” doi:10.1186/s13148-023-01537-2 (https://doi.org/10.1186/s13148-023-01537-2) (salta2023dnamethylationas pages 11-13).
- Seto et al., Nature Communications, Feb 2024. “In vitro induction of patterned branchial arch-like aggregate…” doi:10.1038/s41467-024-45285-0 (https://doi.org/10.1038/s41467-024-45285-0) (seto2024invitroinduction pages 1-2).

Notes on symbol ambiguity
All cited recent literature and functional evidence correspond to human DLX1 or the vertebrate DLX1/2 pair and the DLX family within Homo sapiens developmental or disease contexts; no conflicting organism/gene symbols were used. Domain/family assignments (distal-less homeobox; homeodomain) align across sources (zhu2024transgenicmodelsto pages 46-51, zhu2024transgenicmodelsto pages 51-56).


References

1. (zhu2024transgenicmodelsto pages 46-51): H Zhu. Transgenic models to characterize the role of dlx5 in endochondral ossification. Unknown journal, 2024.

2. (zhu2024transgenicmodelsto pages 51-56): H Zhu. Transgenic models to characterize the role of dlx5 in endochondral ossification. Unknown journal, 2024.

3. (chandrashekar2024amultiloopingchromatin pages 19-22): Harshini Chandrashekar, Zoltan Simandi, Heesun Choi, Han-Seul Ryu, Abraham J. Waldman, Alexandria Nikish, Srikar S. Muppidi, Wanfeng Gong, Dominik Paquet, and Jennifer E. Phillips-Cremins. A multi-looping chromatin signature predicts dysregulated gene expression in neurons with familial alzheimer’s disease mutations. BioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.27.582395, doi:10.1101/2024.02.27.582395. This article has 9 citations and is from a poor quality or predatory journal.

4. (miyoshi2024developmentaltrajectoriesof pages 1-2): Goichi Miyoshi, Yoshifumi Ueta, Yuki Yagasaki, Yusuke Kishi, Gord Fishell, Robert P. Machold, and Mariko Miyata. Developmental trajectories of gabaergic cortical interneurons are sequentially modulated by dynamic foxg1 expression levels. Proceedings of the National Academy of Sciences of the United States of America, Apr 2024. URL: https://doi.org/10.1073/pnas.2317783121, doi:10.1073/pnas.2317783121. This article has 8 citations and is from a highest quality peer-reviewed journal.

5. (deng2024massivelyparallelcharacterization pages 7-8): Chengyu Deng, Sean Whalen, Marilyn Steyert, Ryan Ziffra, Pawel F. Przytycki, Fumitaka Inoue, Daniela A. Pereira, Davide Capauto, Scott Norton, Flora M. Vaccarino, Alex A. Pollen, Tomasz J. Nowakowski, Nadav Ahituv, Katherine S. Pollard, Schahram Akbarian, Alexej Abyzov, Nadav Ahituv, Dhivya Arasappan, Jose Juan Almagro Armenteros, Brian J. Beliveau, Jaroslav Bendl, Sabina Berretta, Rahul A. Bharadwaj, Arjun Bhattacharya, Lucy Bicks, Kristen Brennand, Davide Capauto, Frances A. Champagne, Tanima Chatterjee, Chris Chatzinakos, Yuhang Chen, H. Isaac Chen, Yuyan Cheng, Lijun Cheng, Andrew Chess, Jo-fan Chien, Zhiyuan Chu, Declan Clarke, Ashley Clement, Leonardo Collado-Torres, Gregory M. Cooper, Gregory E. Crawford, Rujia Dai, Nikolaos P. Daskalakis, Jose Davila-Velderrain, Amy Deep-Soboslay, Chengyu Deng, Christopher P. DiPietro, Stella Dracheva, Shiron Drusinsky, Ziheng Duan, Duc Duong, Cagatay Dursun, Nicholas J. Eagles, Jonathan Edelstein, Prashant S. Emani, John F. Fullard, Kiki Galani, Timur Galeev, Michael J. Gandal, Sophia Gaynor, Mark Gerstein, Daniel H. Geschwind, Kiran Girdhar, Fernando S. Goes, William Greenleaf, Jennifer Grundman, Hanmin Guo, Qiuyu Guo, Chirag Gupta, Yoav Hadas, Joachim Hallmayer, Xikun Han, Vahram Haroutunian, Natalie Hawken, Chuan He, Ella Henry, Stephanie C. Hicks, Marcus Ho, Li-Lun Ho, Gabriel E. Hoffman, Yiling Huang, Louise A. Huuki-Myers, Ahyeon Hwang, Thomas M. Hyde, Artemis Iatrou, Fumitaka Inoue, Aarti Jajoo, Matthew Jensen, Lihua Jiang, Peng Jin, Ting Jin, Connor Jops, Alexandre Jourdon, Riki Kawaguchi, Manolis Kellis, Saniya Khullar, Joel E. Kleinman, Steven P. Kleopoulos, Alex Kozlenkov, Arnold Kriegstein, Anshul Kundaje, Soumya Kundu, Cheyu Lee, Donghoon Lee, Junhao Li, Mingfeng Li, Xiao Lin, Shuang Liu, Jason Liu, Jianyin Liu, Chunyu Liu, Shuang Liu, Shaoke Lou, Jacob M. Loupe, Dan Lu, Shaojie Ma, Liang Ma, Michael Margolis, Jessica Mariani, Keri Martinowich, Kristen R. Maynard, Samantha Mazariegos, Ran Meng, Richard M. Myers, Courtney Micallef, Tatiana Mikhailova, Guo-li Ming, Shahin Mohammadi, Emma Monte, Kelsey S. Montgomery, Jill E. Moore, Jennifer R. Moran, Eran A. Mukamel, Angus C. Nairn, Charles B. Nemeroff, Pengyu Ni, Scott Norton, Tomasz Nowakowski, Larsson Omberg, Stephanie C. Page, Saejeong Park, Ashok Patowary, Reenal Pattni, Geo Pertea, Mette A. Peters, Nishigandha Phalke, Dalila Pinto, Milos Pjanic, Sirisha Pochareddy, Katherine S. Pollard, Alex Pollen, Henry Pratt, Pawel F. Przytycki, Carolin Purmann, Zhaohui S. Qin, Ping-Ping Qu, Diana Quintero, Towfique Raj, Ananya S. Rajagopalan, Sarah Reach, Thomas Reimonn, Kerry J. Ressler, Deanna Ross, Panos Roussos, Joel Rozowsky, Misir Ruth, W. Brad Ruzicka, Stephan J. Sanders, Juliane M. Schneider, Soraya Scuderi, Robert Sebra, Nenad Sestan, Nicholas Seyfried, Zhiping Shao, Nicole Shedd, Annie W. Shieh, Joo Heon Shin, Mario Skarica, Clara Snijders, Hongjun Song, Matthew W. State, Jason Stein, Marilyn Steyert, Sivan Subburaju, Thomas Sudhof, Michael Snyder, Ran Tao, Karen Therrien, Li-Huei Tsai, Alexander E. Urban, Flora M. Vaccarino, Harm van Bakel, Daniel Vo, Georgios Voloudakis, Brie Wamsley, Tao Wang, Sidney H. Wang, Daifeng Wang, Yifan Wang, Jonathan Warrell, Yu Wei, Annika K. Weimer, Daniel R. Weinberger, Cindy Wen, Zhiping Weng, Sean Whalen, Kevin P. White, A. Jeremy Willsey, Hyejung Won, Wing Wong, Hao Wu, Feinan Wu, Stefan Wuchty, Dennis Wylie, Siwei Xu, Chloe X. Yap, Biao Zeng, Pan Zhang, Chunling Zhang, Bin Zhang, Jing Zhang, Yanqiong Zhang, Xiao Zhou, Ryan Ziffra, Zane R. Zeier, and Trisha M. Zintel. Massively parallel characterization of regulatory elements in the developing human cortex. Science, May 2024. URL: https://doi.org/10.1126/science.adh0559, doi:10.1126/science.adh0559. This article has 51 citations and is from a highest quality peer-reviewed journal.

6. (dudukcu2024moleculardiversityand pages 10-12): Özge Düdükcü, Divya D.A. Raj, Lieke L. van de Haar, Laurens M. Grossouw, Louisa E. Linders, Oxana Garritsen, Youri Adolfs, Nicky C.H. van Kronenburg, Mark H. Broekhoven, Troy H.W. Kapteijns, Frank J. Meye, and R. Jeroen Pasterkamp. Molecular diversity and migration of gabaergic neurons in the developing ventral midbrain. iScience, 27:111239, Nov 2024. URL: https://doi.org/10.1016/j.isci.2024.111239, doi:10.1016/j.isci.2024.111239. This article has 5 citations and is from a peer-reviewed journal.

7. (chatterjee2024increasedtranslationdriven pages 10-11): Shankha S. Chatterjee, Juan F. Linares, Tania Cid-Diaz, Angeles Duran, Mohd. Imran K. Khan, Marta Osrodek, Nicholas J. Brady, Miguel Reina-Campos, Antonio Marzio, Varadha Balaji Venkadakrishnan, Martin K. Bakht, Francesca Khani, Juan Miguel Mosquera, Brian D. Robinson, Jenna Moyer, Olivier Elemento, Andrew C. Hsieh, David W. Goodrich, David S. Rickman, Himisha Beltran, Jorge Moscat, and Maria T. Diaz-Meco. Increased translation driven by non-canonical ezh2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. Nature Communications, Nov 2024. URL: https://doi.org/10.1038/s41467-024-53874-2, doi:10.1038/s41467-024-53874-2. This article has 8 citations and is from a highest quality peer-reviewed journal.

8. (du2024dlx1actsas pages 1-2): Yu Du, Heng Li, Yan Wang, Yunyan He, and Gaofeng Li. Dlx1 acts as a novel prognostic biomarker involved in immune cell infiltration and tumor progression in lung adenocarcinoma. PeerJ, 12:e16823, Feb 2024. URL: https://doi.org/10.7717/peerj.16823, doi:10.7717/peerj.16823. This article has 0 citations and is from a peer-reviewed journal.

9. (seto2024invitroinduction pages 1-2): Yusuke Seto, Ryoma Ogihara, Kaori Takizawa, and Mototsugu Eiraku. In vitro induction of patterned branchial arch-like aggregate from human pluripotent stem cells. Nature Communications, Feb 2024. URL: https://doi.org/10.1038/s41467-024-45285-0, doi:10.1038/s41467-024-45285-0. This article has 6 citations and is from a highest quality peer-reviewed journal.

10. (hachem2024contemporaryupdateon pages 7-8): Sana Hachem, Amani Yehya, Jad El Masri, Nicole Mavingire, Jabril R. Johnson, Abdulrahman M. Dwead, Naim Kattour, Yazan Bouchi, Firas Kobeissy, Soroush Rais-Bahrami, Yehia Mechref, Wassim Abou-Kheir, and Leanne Woods-Burnham. Contemporary update on clinical and experimental prostate cancer biomarkers: a multi-omics-focused approach to detection and risk stratification. Biology, 13:762, Sep 2024. URL: https://doi.org/10.3390/biology13100762, doi:10.3390/biology13100762. This article has 17 citations and is from a poor quality or predatory journal.

11. (min2025precisionmedicinein pages 7-9): Kang Min, Qing Lin, and Daoxian Qiu. Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers. Cancer Imaging, Sep 2025. URL: https://doi.org/10.1186/s40644-025-00938-1, doi:10.1186/s40644-025-00938-1. This article has 3 citations and is from a peer-reviewed journal.

12. (salta2023dnamethylationas pages 11-13): Sofia Salta, João Lobo, Bruno Magalhães, Rui Henrique, and Carmen Jerónimo. Dna methylation as a triage marker for colposcopy referral in hpv-based cervical cancer screening: a systematic review and meta-analysis. Clinical Epigenetics, Aug 2023. URL: https://doi.org/10.1186/s13148-023-01537-2, doi:10.1186/s13148-023-01537-2. This article has 52 citations and is from a peer-reviewed journal.

## Citations

1. zhu2024transgenicmodelsto pages 46-51
2. chandrashekar2024amultiloopingchromatin pages 19-22
3. miyoshi2024developmentaltrajectoriesof pages 1-2
4. deng2024massivelyparallelcharacterization pages 7-8
5. dudukcu2024moleculardiversityand pages 10-12
6. chatterjee2024increasedtranslationdriven pages 10-11
7. seto2024invitroinduction pages 1-2
8. zhu2024transgenicmodelsto pages 51-56
9. hachem2024contemporaryupdateon pages 7-8
10. min2025precisionmedicinein pages 7-9
11. salta2023dnamethylationas pages 11-13
12. https://doi.org/10.1126/science.adh0559
13. https://doi.org/10.1101/2024.02.27.582395
14. https://doi.org/10.1073/pnas.2317783121
15. https://doi.org/10.1038/s41467-024-53874-2
16. https://doi.org/10.3390/biology13100762
17. https://doi.org/10.7717/peerj.16823
18. https://doi.org/10.1186/s13148-023-01537-2
19. https://doi.org/10.1038/s41467-024-45285-0
20. https://doi.org/10.1101/2024.02.27.582395,
21. https://doi.org/10.1073/pnas.2317783121,
22. https://doi.org/10.1126/science.adh0559,
23. https://doi.org/10.1016/j.isci.2024.111239,
24. https://doi.org/10.1038/s41467-024-53874-2,
25. https://doi.org/10.7717/peerj.16823,
26. https://doi.org/10.1038/s41467-024-45285-0,
27. https://doi.org/10.3390/biology13100762,
28. https://doi.org/10.1186/s40644-025-00938-1,
29. https://doi.org/10.1186/s13148-023-01537-2,